Drugs

Lomitapide

Pharmacogenomic Information
  

DrugTherapeutic Area*BiomarkerReferenced
Subgroup
Labeling Sections

Lomitapide

EndocrinologyLDLRLDLR mutation homozygotes (homozygous familial
hypercholesterolemia) 
 
Indication and Usage, Warnings and Precautions, Adverse Reactions, Clinical Studies

 

* Therapeutic areas do not necessarily reflect the CDER review division.
 
 
 
 
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.

 

back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 04/16/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.